Quantcast
Last updated on April 23, 2014 at 15:23 EDT

Latest Small interfering RNA Stories

2013-08-07 12:27:01

DUBLIN, August 7, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/2bqb4m/rnai) has announced the addition of new report "RNAi - Technologies, Markets and Companies [http://www.researchandmarkets.com/research/2bqb4m/rnai ]" to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) RNA interference (RNAi) or gene silencing involves the use of double stranded RNA (dsRNA). Once inside the cell, this material...

2013-07-09 22:54:58

The approach points the way toward new ways to silence malfunctioning genes Silencing genes that have malfunctioned is an important approach for treating diseases such as cancer and heart disease. One effective approach is to deliver drugs made from small molecules of ribonucleic acid, or RNA, which are used to inhibit gene expression. The drugs, in essence, mimic a natural process called RNA interference. In a new paper appearing today online in the journal, ACS Medicinal Chemistry...

2013-06-28 12:24:07

DUBLIN, June 28, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/42wzs7/global) has announced the addition of the "Global Transfection (Gene Delivery, DNA Delivery, Protein Delivery, SiRNA Delivery) Technologies (Lipofection, Calcium Phosphate, Electroporation, Nucleofection, Magnetofection, Gene Gun, Viral) Market (2012 - 2017)" [http://www.researchandmarkets.com/research/42wzs7/global ] report to their offering. (Logo:...

2013-06-19 08:28:59

Invivofectamine® Rx-formulated therapeutic is 100-fold more potent than previous in-vivo transfection products from Life CARLSBAD, Calif., June 19, 2013 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announces a licensing agreement granting Suzhou Ribo Life Sciences (Ribo) the exclusive rights to develop and manufacture siRNA therapeutics in China using Life's Invivofectamine® Rx delivery technology. Ribo will formulate proprietary siRNA molecules...

2013-06-03 08:26:51

Financing from High Net-Worth Private Investors to Fuel RNAi Delivery Technologies for the Treatment of Disease SAN DIEGO, June 3, 2013 /PRNewswire/ -- Arcturus Therapeutics, Inc., an industry leader in RNAi technologies for the treatment of disease, today announced it has raised $1.3 million in a seed funding round led by multiple high net-worth private investors from the United States and Canada. (Logo: http://photos.prnewswire.com/prnh/20130531/MM24393LOGO) Arcturus...

2013-04-26 23:04:47

Altogen Labs is a GLP compliant laboratory that provides preclinical research and biology contract research services (CRO). Altogen Labs now offers wide variety of preclinical CRO services, including drug development, generation of stable cell lines, RNAi gene silencing and in vivo research services (xenograft, in vivo siRNA delivery), pharm/tox assays (IC50), cell banking, and ELISA assay development. Austin, TX (PRWEB) April 26, 2013 Altogen Labs, a biotechnology company focused on...

2013-04-25 08:33:23

DUBLIN, April 25, 2013 /PRNewswire/ -- Research and Markets announces the addition of "Global Transfection (Gene Delivery, DNA Delivery, Protein Delivery, SiRNA Delivery) Technologies Market (2012 - 2017)" to its catalogue.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Transfection is an enabler technology used for many cell based research activities with applications spanning production of recombinant proteins and recombinant cell lines, gene therapy,...

2013-04-12 12:24:34

DUBLIN, April 12, 2013 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Transfection (Gene Delivery, DNA Delivery, Protein Delivery, SiRNA Delivery) Technologies (Lipofection, Calcium Phosphate, Electroporation, Nucleofection, Magnetofection, Gene Gun, Viral) Market (2012 - 2017)" [http://www.researchandmarkets.com/research/r35jnt/global ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Transfection...

2013-01-20 23:02:04

[130 Slides Report]Global Transfection Technologies Market (Lipofection, Calcium Phosphate, Electroporation, Nucleofection, Magnetofection, Gene Gun, Viral) And Types (Gene Delivery, DNA Delivery, Protein Delivery, SiRNA Delivery) (2012 — 2017) (PRWEB) January 20, 2013 The report "Global Transfection Technologies Market - (Lipofection, Calcium Phosphate, Electroporation, Nucleofection, Magnetofection, Gene Gun, Viral) And Types (Gene Delivery, DNA Delivery, Protein Delivery, SiRNA...

2012-12-19 12:24:43

GAITHERSBURG, Md., Dec. 19, 2012 /PRNewswire/ -- Sirnaomics, Inc. (www.sirnaomics.com) announced today that the company has made a major breakthrough in its novel small interfering RNA (siRNA) therapeutic product against human papillomavirus (HPV) infection and cervical cancer which was presented by Dr. Alan Lu, Executive Vice President of Sirnaomics, in the 28(th) International Papillomavirus Conference held in San Juan, Puerto Rico from Nov 30(th) to Dec 6(th), 2012. Dr. Lu's presentation...